NSPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
InspireMD Inc (NSPR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows promising growth potential, supported by strong revenue growth, improving financial metrics, and a positive analyst rating with a $6 price target. While there are no immediate trading signals or significant news catalysts, the technical indicators and options data suggest a neutral to slightly bullish sentiment, making it a reasonable entry point for long-term investment.
The MACD histogram is positive at 0.0223, indicating bullish momentum, though it is contracting. RSI is neutral at 50.643, suggesting no overbought or oversold conditions. Moving averages are converging, indicating a consolidation phase. The stock is trading at its pivot level of $1.7, with resistance at $1.797 and support at $1.602. Overall, the technical indicators suggest a neutral to slightly bullish trend.
Revenue increased by 39.39% YoY in Q3
Gross margin improved significantly by 49.72% YoY.
Analyst coverage initiated with a Buy rating and a $6 price target.
Stock trend analysis suggests an 8.49% potential increase in the next month.
No recent news or event-driven catalysts.
Net income remains negative despite improvement.
No significant hedge fund or insider trading activity.
In Q3 2025, InspireMD reported a revenue increase of 39.39% YoY to $2,523,000. Net income improved by 61.06% YoY but remains negative at -$12,708,000. EPS improved by 6.25% YoY to -0.17. Gross margin increased significantly by 49.72% YoY to 34.24%. Overall, the company is showing strong growth trends despite ongoing losses.
Maxim initiated coverage of InspireMD with a Buy rating and a $6 price target on February 2, 2026, indicating strong confidence in the stock's long-term potential.
